scispace - formally typeset
U

Urban Emmenegger

Researcher at Sunnybrook Health Sciences Centre

Publications -  150
Citations -  9101

Urban Emmenegger is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 31, co-authored 117 publications receiving 8215 citations. Previous affiliations of Urban Emmenegger include Women's College, Kolkata & European Institute of Oncology.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

Yuval Shaked, +17 more
- 09 Sep 2008 - 
TL;DR: It is shown that certain chemotherapy drugs, e.g., paclitaxel, can rapidly induce proangiogenic bone marrow-derived circulating endothelial progenitor (CEP) mobilization and subsequent tumor homing, whereas others do not.
Journal ArticleDOI

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Yuval Shaked, +12 more
- 01 Nov 2005 - 
TL;DR: The results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens, and the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term with targeted therapies can be compromised.
Journal ArticleDOI

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies

Guido Bocci, +13 more
- 15 Sep 2004 - 
TL;DR: Plasma VEGF should be considered as a possible surrogate pharmacodynamic marker for determining the optimal biological dose of antibody drugs that block VEGFR-2 (KDR) activity in a clinical setting.
Journal ArticleDOI

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Jeanne Michelle du Manoir, +8 more
- 01 Feb 2006 - 
TL;DR: The results provide a possible additional rationale for combined biological therapy using drugs that target both erbB-2/HER2 and VEGF and also suggest the potential value of combining less toxic metronomic chemotherapy regimens not only with targeted antiangiogenic agents but also with other types of drug such as trastuzumab.